Nonradiological Treatment for Lung Tumors



Lung cancer is a major public health problem. In the USA, approximately 220,000 patients are diagnosed annually and 160,000 die, far more than from prostate or breast cancer (American Cancer Society 2010 Cancer Statistics). Worldwide, lung cancer is the leading cause of cancer mortality, and the World Health Organization estimates 1.3 million deaths per year. The 5-year survival rate is only approximately 15%, and this survival has not changed dramatically over the past three decades.


National Comprehensive Cancer Network National Comprehensive Cancer Network Intensity Modulate Radiation Therapy Stereotactic Body Radiation Therapy Radiation Therapy Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer. 2010;67(3):257–74. Epub 2009 Nov 14.Google Scholar
  2. 2.
    AJCC Cancer Staging Handbook. American Joint Committee On Cancer. 7th ed. New York: Springer; 2010.Google Scholar
  3. 3.
    Azzoli CG, Baker Jr S, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–66. Epub 2009 Nov 16.PubMedCrossRefGoogle Scholar
  4. 4.
    Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW, American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd ed.). Chest. 2007;132(3 Suppl):243 S–65 S.Google Scholar
  5. 5.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, non-small cell lung cancer, v2.2010. Accessed 1 Dec 2010.
  6. 6.
    Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al., Cancer Care Ontario, American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25(34):5506–18. Epub 2007 Oct 22.Google Scholar
  7. 7.
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126–31. Epub 2009 Nov 16.PubMedCrossRefGoogle Scholar
  8. 8.
    Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132(1):193–9. Epub 2007 May 15.PubMedCrossRefGoogle Scholar
  9. 9.
    Morrison R, Deeley TJ, Cleland WP. The treatment of carcinoma of the bronchus: a clinical trial to compare surgery and supervoltage radiotherapy. Lancet. 1963;281(7283):683–4.CrossRefGoogle Scholar
  10. 10.
    National Institute for Clinical Excellence. The diagnosis and treatment of lung cancer: methods, evidence, and guidance. Accessed 1 Dec 2010.
  11. 11.
    Jensik RJ, Faber LP, Millov FJ, et al. Segmental resection for lung cancer – a fifteen-year experience. J Thorac Cardiovasc Surg. 1973;66:563–72.PubMedGoogle Scholar
  12. 12.
    Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–22. discussion 622–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Lederle FA. Lobectomy versus limited resection in T1 N0 lung cancer. Ann Thorac Surg. 1996;62(4):1249–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Okada M, Yoshikawa K, Hatta T, Tsubota N. Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller? Ann Thorac Surg. 2001;71(3):956–60. discussion 961.PubMedCrossRefGoogle Scholar
  15. 15.
    Koike T, Yamato Y, Yoshiya K, Shimoyama T, Suzuki R. Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. J Thorac Cardiovasc Surg. 2003;125(4):924–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis. Br J Cancer. 2005;92(6):1033–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Chamogeorgakis T, Ieromonachos C, Georgiannakis E, Mallios D. Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg. 2009;8(3):364–72. Epub 2008 Jul 18.PubMedCrossRefGoogle Scholar
  18. 18.
    Mery CM, Pappas AN, Bueno R, Colson YL, Linden P, Sugarbaker DJ, et al. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database. Chest. 2005;128(1):237–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Lyons G, Quadrelli S, Silva C, Vera K, Iotti A, et al. Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor. J Thorac Oncol. 2008;3(9):989–93.PubMedCrossRefGoogle Scholar
  20. 20.
    British Thoracic Society, Society of Cardiothoracic Surgeons of Great Britain and Ireland Working Party. BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax. 2001;56(2):89–108.Google Scholar
  21. 21.
    Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT, American College of Chest Physicians. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd ed.). Chest. 2007;132(3 Suppl):161 S–77 S.Google Scholar
  22. 22.
    Lee W, Daly BD, DiPetrillo TA, Morelli DM, Neuschatz AC, Morr J, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds. Ann Thorac Surg. 2003;75(1):237–42. discussion 242–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Santos R, Colonias A, Parda D, Trombetta M, Maley RH, Macherey R, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. Surgery. 2003;134(4):691–7. discussion 697.PubMedCrossRefGoogle Scholar
  24. 24.
    Qiao X, Tullgren O, Lax I, Sirzén F, Lewensohn R. The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer. 2003;41(1):1–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Wisnivesky JP, Bonomi M, Henschke C, Iannuzzi M, McGinn T. Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. Chest. 2005;128(3):1461–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;49(1):23–33.PubMedCrossRefGoogle Scholar
  27. 27.
    Bradley J, Graham MV, Winter K, Purdy JA, Komaki R, Roa WH, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys. 2005;61(2):318–28.PubMedCrossRefGoogle Scholar
  28. 28.
    Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2 N0) non-small cell lung cancer. Radiother Oncol. 1996;41(1):41–4.PubMedCrossRefGoogle Scholar
  29. 29.
    Bush DA, Slater JD, Bonnet R, Cheek GA, Dunbar RD, Moyers M, et al. Proton-beam radiotherapy for early-stage lung cancer. Chest. 1999;116(5):1313–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004;126(4):1198–203.PubMedCrossRefGoogle Scholar
  31. 31.
    Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65(1):107–11.PubMedCrossRefGoogle Scholar
  32. 32.
    Hata M, Tokuuye K, Kagei K, Sugahara S, Nakayama H, Fukumitsu N, et al. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys. 2007;68(3):786–93. Epub 2007 Mar 26.PubMedCrossRefGoogle Scholar
  33. 33.
    McGarry RC, Papiez L, Williams M, Whitford T, Timmerman RD. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005;63(4):1010–5. Epub 2005 Aug 22.PubMedCrossRefGoogle Scholar
  34. 34.
    Timmerman R et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(110):1070–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Wulf J, Baier K, Mueller G, Flentje MP. Dose–response in stereotactic irradiation of lung tumors. Radiother Oncol. 2005;77(1):83–7. Epub 2005 Oct 4.PubMedCrossRefGoogle Scholar
  36. 36.
    Hara R, Itami J, Kondo T, Aruga T, Uno T, Sasano N, et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors. Cancer. 2006;106(6):1347–52.PubMedCrossRefGoogle Scholar
  37. 37.
    Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94–100.PubMedCrossRefGoogle Scholar
  38. 38.
    Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys. 2009;75(2):343–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Sahn SA, Nett LM, Petty TL. Ten year follow-up of a comprehensive rehabilitation program for severe COPD. Chest. 1980;77(2 Suppl):311–4.PubMedCrossRefGoogle Scholar
  40. 40.
    D’Cunha J, Herndon JE 2nd, Herzan DL, Patterson GA, Kohman LJ, Harpole DH et al., Cancer and Leukemia Group B. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005;48(2):241–6. Epub 2005 Jan 4.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Radiation OncologyMD Anderson Cancer Center OrlandoOrlandoUSA
  2. 2.Department of Radiation OncologyRhode Island HospitalProvidenceUSA

Personalised recommendations